Ryan Reynolds Announces More to Parkinson’s® Campaign
Ryan Reynolds and Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) have launched the 'More to Parkinson's®' campaign to raise awareness about Parkinson's-related hallucinations and delusions. These non-motor symptoms affect around 50% of Parkinson's patients, but up to 90% don't report them to their doctors. Reynolds and his mother Tammy share their experiences caring for Ryan's late father, who had Parkinson's disease, to educate others about these under-recognized symptoms.
The campaign aims to encourage open discussions between patients, caregivers, and healthcare providers about managing these symptoms. It includes videos and resources on MoretoParkinsons.com, covering topics such as risk factors, symptom identification, and treatment options. The initiative seeks to address the significant gap in awareness and understanding of these non-motor symptoms, which can be more distressing than motor symptoms associated with Parkinson's disease.
Ryan Reynolds e Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) hanno lanciato la campagna 'More to Parkinson's®' per sensibilizzare sull'hallucinations e delusions legate al Parkinson. Questi sintomi non motori colpiscono circa il 50% dei pazienti affetti da Parkinson, ma fino al 90% di essi non li riferisce ai propri medici. Reynolds e sua madre Tammy condividono le loro esperienze nel prendersi cura del defunto padre di Ryan, che soffriva di Parkinson, per educare gli altri su questi sintomi poco riconosciuti.
La campagna mira a incoraggiare discussioni aperte tra pazienti, caregiver e professionisti della salute sulla gestione di questi sintomi. Include video e risorse su MoretoParkinsons.com, trattando argomenti come fattori di rischio, identificazione dei sintomi e opzioni di trattamento. L'iniziativa cerca di colmare il significativo divario nella consapevolezza e comprensione di questi sintomi non motori, che possono essere più angoscianti rispetto ai sintomi motori associati alla malattia di Parkinson.
Ryan Reynolds y Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) han lanzado la campaña 'More to Parkinson's®' para aumentar la conciencia sobre las alucinaciones y delirios relacionados con el Parkinson. Estos síntomas no motores afectan a alrededor del 50% de los pacientes con Parkinson, pero hasta el 90% no los informan a sus médicos. Reynolds y su madre Tammy comparten sus experiencias cuidando a su difunto padre, quien padecía la enfermedad de Parkinson, para educar a otros sobre estos síntomas poco reconocidos.
La campaña tiene como objetivo fomentar conversaciones abiertas entre pacientes, cuidadores y proveedores de salud sobre el manejo de estos síntomas. Incluye videos y recursos en MoretoParkinsons.com, que abordan temas como factores de riesgo, identificación de síntomas y opciones de tratamiento. La iniciativa busca abordar la significativa brecha en la conciencia y comprensión de estos síntomas no motores, que pueden ser más angustiantes que los síntomas motores asociados con la enfermedad de Parkinson.
Ryan Reynolds와 Acadia Pharmaceuticals Inc. (Nasdaq: ACAD)는 'More to Parkinson's®' 캠페인을 시작하여 파킨슨병 관련 환각과 망상에 대한 인식을 높이고 있습니다. 이러한 비운동 증상은 파킨슨 병 환자의 약 50%에게 영향을 미치지만, 최대 90%는 이를 의사에게 보고하지 않습니다. 레이놀즈와 그의 어머니 탬미는 파킨슨병을 앓고 있었던 고인의 아버지를 돌보는 경험을 공유하며 이러한 잘 인식되지 않은 증상에 대해 다른 사람들과 교육합니다.
이 캠페인은 환자, 간병인 및 의료 제공자 간의 이러한 증상 관리에 대한 개방적인 논의를 장려하는 것을 목표로 합니다. MoretoParkinsons.com에서 위험 요소, 증상 식별, 치료 옵션과 같은 주제를 다루는 비디오 및 자료가 포함되어 있습니다. 이 이니셔티브는 파킨슨병과 관련된 운동 증상보다 더 괴롭힐 수 있는 이러한 비운동 증상에 대한 인식과 이해의 격차를 해소하고자 합니다.
Ryan Reynolds et Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) ont lancé la campagne 'More to Parkinson's®' pour sensibiliser aux hallucinations et délires liés à la maladie de Parkinson. Ces symptômes non moteurs affectent environ 50 % des patients atteints de Parkinson, mais jusqu'à 90 % ne les signalent pas à leurs médecins. Reynolds et sa mère Tammy partagent leurs expériences de soin pour le père de Ryan, décédé et atteint de la maladie de Parkinson, afin d'informer les autres sur ces symptômes peu reconnus.
La campagne vise à encourager des discussions ouvertes entre les patients, les aidants et les prestataires de soins de santé sur la gestion de ces symptômes. Elle comprend des vidéos et des ressources sur MoretoParkinsons.com, abordant des sujets tels que les facteurs de risque, l'identification des symptômes et les options de traitement. L'initiative cherche à combler le fossé significatif dans la prise de conscience et la compréhension de ces symptômes non moteurs, qui peuvent être plus éprouvants que les symptômes moteurs associés à la maladie de Parkinson.
Ryan Reynolds und Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) haben die Kampagne 'More to Parkinson's®' ins Leben gerufen, um das Bewusstsein für Parkinsons bedingte Halluzinationen und Wahnvorstellungen zu schärfen. Diese nicht-motorischen Symptome betreffen etwa 50 % der Parkinson-Patienten, aber bis zu 90 % berichten nicht darüber ihren Ärzten. Reynolds und seine Mutter Tammy teilen ihre Erfahrungen bei der Pflege von Ryans verstorbenem Vater, der an Parkinson erkrankt war, um andere über diese wenig bekannten Symptome aufzuklären.
Die Kampagne zielt darauf ab, offene Gespräche zwischen Patienten, Betreuern und Gesundheitsdienstleistern über die Bewältigung dieser Symptome zu fördern. Sie umfasst Videos und Ressourcen auf MoretoParkinsons.com, die Themen wie Risikofaktoren, Symptomerkennung und Behandlungsoptionen abdecken. Die Initiative soll die erhebliche Lücke im Bewusstsein und Verständnis dieser nicht-motorischen Symptome schließen, die belastender sein können als die mit Parkinson verbundenen motorischen Symptome.
- Launch of 'More to Parkinson's®' campaign to raise awareness about Parkinson's-related hallucinations and delusions
- Partnership with high-profile celebrity Ryan Reynolds to increase campaign visibility and reach
- Potential for increased awareness to lead to better diagnosis and treatment of Parkinson's symptoms
- Multichannel campaign approach including digital media, social media, and connected TV to reach a wide audience
- None.
-- The national disease awareness campaign aims to educate and drive conversation about recognizing and managing non-motor symptoms of Parkinson’s, including hallucinations and delusions
-- Reynolds and his mother Tammy share their personal story about the impact of these symptoms on their family
Ryan & Tammy Reynolds (Photo: Business Wire)
Notably, around half of the people living with Parkinson’s disease may develop hallucinations or delusions over the course of their disease, but up to
“My father experienced hallucinations and delusions. At the time, we didn’t know any of these types of symptoms were part of his Parkinson’s disease,” Reynolds explains. “Like a lot of caregivers, my mom mostly tried to carry these burdens alone. I wish I’d known Parkinson’s disease wasn’t limited to only motor symptoms. I think people and families affected by Parkinson’s can be better prepared to manage hallucinations and delusions if they’re talking early and often about this lesser-known aspect of the disease.”
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/54103329/en.
“In my experience, most people living with Parkinson’s disease who experience hallucinations and delusions do not proactively tell their physicians about them unless specifically asked,” explains Dr. Yasar Torres-Yaghi, attending physician, director of Parkinsonism and Dementia Clinic at Georgetown University Hospital,
More to Parkinson’s is an educational campaign, sponsored by Acadia Pharmaceuticals Inc., that aims to increase awareness among caregivers and patients of the existence of hallucinations and delusions as common parts of Parkinson’s disease. The campaign is anchored by a series of stories shared by Ryan and his mother, Tammy, as they relay their personal experiences from the perspective of a son and caregiver as well as a wife, mother, and caregiver, over the course of Jim’s disease. The multichannel campaign includes videos spanning a wide range of topics focusing on Parkinson’s-related hallucinations and delusions, covering who is at risk, what symptoms may look like, how to discuss symptoms and treatment options with a doctor, and more. The campaign will strive to reach the Parkinson’s disease community through digital media, social media and connected TV.
“There is a significant gap in awareness and understanding that hallucinations and delusions can be part of the progression of Parkinson’s disease,” said Steve Davis, Chief Executive Officer, Acadia. “As Ryan’s family story makes evident, the non-motor symptoms of Parkinson’s, including hallucinations and delusions, are often more distressing and disruptive than the motor symptoms associated with the disease. We are honored that Ryan and Tammy are willing to share their powerful story. Their experiences will open the door to desperately needed conversation and encourage people to speak with their healthcare providers about managing these symptoms.”
To learn more, visit MoretoParkinsons.com to find resources, including doctor and family discussion guides, and hear stories from people who have been affected by Parkinson’s-related hallucinations and delusions.
About Parkinson’s Disease and Parkinson’s-Related Hallucinations and Delusions
Parkinson’s disease is a progressive nervous system disorder that affects about one million people in
About Acadia Pharmaceuticals Inc.
Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the treatment options for people living with hallucinations and delusions associated with Parkinson’s disease and Rett syndrome. Our clinical-stage development efforts are focused on treating, Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at Acadia.com and follow us on LinkedIn and Twitter.
References
1 Forsaa EB, Larsen JP, Wentzel-Larsen T, et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol. 2010;67(8):996-1001.
2 Fénelon G, Mahieux F, Huon R, Ziégler M. Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain. 2000;123(Pt 4):733-745.
3 Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, et al. The nondeclaration of nonmotor symptoms of Parkinson’s disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord. 2010;25(6):704-709.
4 Parkinson’s Foundation. What is Parkinson’s? Retrieved from https://www.parkinson.org/Understanding-Parkinsons/Statistics. Accessed March 1, 2024.
5 Marras C, Beck JC, Bower JH, et al.; Parkinson’s Foundation P4 Group. Prevalence of Parkinson's disease across
6 Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS, NIMH work group. Mov Disord. 2007 Jun 15;22(8):1061-8.
7 Martinez-Martin P, Schapira AHV, et al. Prevalence of Nonmotor Symptoms in Parkinson’s Disease in an International Setting: Study using Nonmotor Symptoms Questionnaire in 545 Patients. Mov Disord. 2007; 22(11): 1623-1629.
8 Olanow CW, Schapira AHV. 2012. Parkinson’s Disease and Other Movement Disorders. Fauci AS (Ed), Harrison’s Principles of Internal Medicine (18th ed.).
9 Martinez-Martin P, Rodriguez-Blazquez C, et al. The Impact of Non-Motor Symptoms on Health Related Quality of Life of Patients with Parkinson’s Disease. Mov Disord. 2011;26(3):399-406.
10 Aarsland D, Bronnick K, Ehrt U, et al. Neuropsychiatric symptoms in patients with Parkinson’s disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry. 2007;78:36-42.
11 Schrag A, Hovris A, et al. Caregiver-burden in parkinson’s disease is closely associated with psychiatric symptoms, falls, and disability. Parkinsonism and Related Disorders. 2006;12:35-41.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240801386480/en/
Investor Contact:
Acadia Pharmaceuticals Inc.
Al Kildani
(858) 261-2872
ir@acadia-pharm.com
Media Contact:
Acadia Pharmaceuticals Inc.
Deb Kazenelson
(818) 395-3043
media@acadia-pharm.com
Source: Acadia Pharmaceuticals Inc.
FAQ
What is the 'More to Parkinson's®' campaign launched by Ryan Reynolds and ACAD?
How prevalent are hallucinations and delusions in Parkinson's disease patients?
What resources does the 'More to Parkinson's®' campaign provide?
Why did Ryan Reynolds get involved with the ACAD campaign for Parkinson's awareness?
